Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that Dr. Matthew Regulski, Medical Director of the Wound Institute of New Jersey, will present clinical trial data, including secondary endpoints, from Osiris’ multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® in patients with chronic diabetic foot ulcers tomorrow, November 20th, at the 10th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona. The trial met all primary, secondary and safety endpoints and demonstrated a statistically significant reduction in infections and hospitalizations for patients treated with Grafix compared to conventional therapy.
Help employers find you! Check out all the jobs and post your resume.
